Oncolysin S (ImmunoGen)

N/A

Report date: 2022/03/04 16:16:53

Base Information

Drug NameOncolysin S (ImmunoGen)

Drug Alias NameN901-BRN901-blocked ricin

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionProtein biosynthesis inhibitorsAnti-NCAM1

TargetsNeural cell adhesion molecule 1

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A